A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022. This article highlights Tecovirimat’s development and patent literature review and is b...

Full description

Bibliographic Details

Published in:	Viruses
Main Authors:	Mazen Almehmadi, Mamdouh Allahyani, Ahad Amer Alsaiari, Mohammed Kanan Alshammari, Abrar Saleh Alharbi, Khansa Hamza Hussain, Lojain Ibrahim Alsubaihi, Mehnaz Kamal, Shahad Saleh Alotaibi, Atheer Nasser Alotaibi, Afeefah Awaid Aldhafeeri, Mohd Imran
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Subjects:	Tecovirimat SIGA-246 TPOXX orthopoxvirus monkeypox patents
Online Access:	https://www.mdpi.com/1999-4915/14/9/1870